Effect of some analgesics on Paraoxonase-1 purified from human serum

References

• Rodrigo L, Gil F, Hernandez AF, Lopez O, Pla A. Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. Biochem J 2003;376:261–268.
   PubMed Web of Science ®Google Scholar
• La Du BN. Human serum paraoxonase/arylesterase, In Pharmacogenetics of Drug Metabolism (Kalow, W., ed.). Pergamon, Elmford, NY; 1992. p 51–91.
   Google Scholar
• Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334–336.
   PubMed Web of Science ®Google Scholar
• Billecke S, Draganov D, Councell R, Stetson P, Watson C, Hsu C, La Du BN. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335–1342.
   PubMed Web of Science ®Google Scholar
• Lu H, Zhu J, Zang Y, Ze Y, Qın J. Cloning, purifcation, and refolding of human paraoxonase-3 expressed in Escherichia coli and its characterization. Protein Expres Purif 2006;46:92–99.
   PubMed Web of Science ®Google Scholar
• Durringhton PN, Mackness B, Mackness MJ. Paraoxonase and atherosclerosis. Arterioscl Throm and Vas 2001;21:473–480.
   PubMed Web of Science ®Google Scholar
• Primo-Parmo SL, Sorenson RS, Teiber J, La Du BN. The human serum paraoxonase / arylesterase gen (PON1) is one member of a multigene family. Genomics 1996;33:498–507.
   PubMed Web of Science ®Google Scholar
• La Du N, Aviram S, Billecke M, Navabc M, Primo-Parmoa S, Sorensona RC, Standifordd TJ. On the physiological role(s) of the paraoxonases. Chem-Biol Interac 1999;119–120:379–388.
   PubMed Web of Science ®Google Scholar
• Sinan S, Kockar F, Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie 2006;88:565–574.
   PubMed Web of Science ®Google Scholar
• Costa LG, Li WF, Richter RJ, Shihc DM, Lusisc A, Furlongb CE. The role of paraoxonase (PON1) in the detoxification of organophosphates and its human polymorphism. Chem-Biol Interac 1999;119–120:439–444.
   PubMed Web of Science ®Google Scholar
• Golmanesh L, Mehrani H, Tabei M. Simple procedures for purification and stabilization of human serum paraoxonase-1. J Biochem and Bioph Meth 2008;70:1037–42.
   PubMedGoogle Scholar
• Furlong CE, Li WF, Brophy VH, Jarvik GP, Richter RJ, Shih DM, Lusis AJ, Costa LG. The PON1 gene and detoxication. Neurotoxicology 2000;21:581–588.
   PubMed Web of Science ®Google Scholar
• Josse D, Masson P. Human plasma paraoxonase (HUPON1): an atherogenic enzyme with organophosphate hydrolase activity. Ann Pharmaceut Fran 2001;59:108–118.
   PubMedGoogle Scholar
• Aharoni A, Gaidukov L, Khersonsky O, Gould SM, Roodveldt C, Tawfik DS. The ‘evolvability’ of promiscuous protein functions. Nat Genet 2005;37:73–76.
   PubMed Web of Science ®Google Scholar
• Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry-US 2005;44: 6371–6382.
   PubMed Web of Science ®Google Scholar
• Rochua D, Chabri`ere E, Massona P. Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007;233:47–59.
   PubMed Web of Science ®Google Scholar
• Nguyen SD, Sok DE. Preferable stimulation of PON1 arylesterase activity by phosphatidylcholines with unsaturated acyl chains or oxidized acyl chains at sn-2 position. BBA Biomembranes 2006;1758:499–508.
   PubMed Web of Science ®Google Scholar
• Akgur SA, Ozturk P, Solak I, Moralb AR, Ege B. Human serum paraoxonase (PON1) activity in acute organophosphorus insecticide poisoning. Forensic Sci Int 2003;133:136–140.
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Bio Med 1999;26:892–904.
   PubMed Web of Science ®Google Scholar
• Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM, La Du BN. Mildly oxidized LDL induces an increased apolipoprotein J/ paraoxonase ratio. J Clin Invest 1997;99:2005–19.
   PubMed Web of Science ®Google Scholar
• McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671–3.
   PubMed Web of Science ®Google Scholar
• Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscl Throm and Vas 1995;15:1812–18.
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJM, Durrington PN. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341–9.
   PubMed Web of Science ®Google Scholar
• Sakai T, Matsuura B, Onji M. Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Internal Med 1998;37:581–4.
   PubMed Web of Science ®Google Scholar
• Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082–2088.
   PubMed Web of Science ®Google Scholar
• Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, Muhtaroglu S. Assessment of Paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 2005;38:951–955.
   PubMed Web of Science ®Google Scholar
• Raiszadeh F, Solati M, Etemadi A, Azizi F. Serum paraoxonase activity before and after treatment of thyrotoxicosis.Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clin Endocrinol 2004;60:75–80.
   PubMed Web of Science ®Google Scholar
• Baskol G, Karakucuk S, Oner AO, Baskol M, Kocer D, Mirza E, Saraymen R, Ustdal M, Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 2006;220:12–16.
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882–2891.
   PubMed Web of Science ®Google Scholar
• Rodrigo L, Gil F, Hernandez AF, Marina A, Vazquez J, Pla A, Purification and characterization of paraoxon hydrolase from rat liver. Biochem J 1997;321:595–601.
   PubMed Web of Science ®Google Scholar
• Çiftçi M, Beydemir ş, Yılmaz H, Bakan E. Effects of some drugs on rat erythrocyte 6-phosphogluconate dehydrogenase: an in vitro and in vivo study. Pol J Pharmacol 2002;54:275–280.
   PubMedGoogle Scholar
• Beydemir Ş, Gülçin İ, Küfrevioğlu Öİ, çiftci M. Glucose 6-phosphate dehydrogenase: In vitro and in vivo effects of dantrolene sodium. Pol J Pharmacol 2003;55:787–792.
   PubMedGoogle Scholar
• Ekinci D, Beydemir ş, Alım Z. Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II. Pharmacol Rep 2007;59:580–587.
   PubMed Web of Science ®Google Scholar
• Malin R, Laaksonen R, Knuuti J, Janatuinen T, Vesalainen R, Nuutila P, Lehtimäki T. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 2001;11:625–633.
   PubMedGoogle Scholar
• Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, MarrugatJ. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscl Throm and Vas 2000;20:2113–2119.
   PubMed Web of Science ®Google Scholar
• Leviev I, James R. Simvastatin increases plasma levels of the antioxidant enzyme paraoxonase by PON1 gene activation, Atherosclerosis 2000;151:41.
   Google Scholar
• Renault F, Chabrière E, Andrieu JP, Dublet B, Massona P, Rochua D, Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. J Chromatogr B 2006;836:15–21.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 48–251.
   Web of Science ®Google Scholar
• Laemli DK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970;227:680–683.
   PubMed Web of Science ®Google Scholar
• Lineweaver H, Burk D, The determination of enzyme dissocation constants. J Am Chem Soc 1934;57:685.
   Google Scholar
• La Du BN. Structural and functional diversity of paraoxonases. Nat Med 1996;2: 1186–1187.
   PubMed Web of Science ®Google Scholar
• Alici HA, Ekinci D, Beydemir ş. Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo. Clin Bioch 2008 ;(in press).
   PubMed Web of Science ®Google Scholar
• Shadnia S, Azizi E, Hosseini R, Khoei S, Fouladdel S, Pajoumand A, Jalali N, Abdollahi M. Evaluation of oxidative stress and genotoxicity in organophosphorus insecticide formulators. Hum Exp Toxicol 2005;9:439–445.
   Web of Science ®Google Scholar
• Ashani Y, Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci 2004;77:358–367.
   PubMed Web of Science ®Google Scholar
• Hochster RM, Kates M, Quastel JH. Metabolic Inhibitors, New York: Academic Press, 1973.
   Google Scholar
• Christensen GM, Olson D, Riedel B. Chemical effects on the activity of eight enzymes: a review and a discussion relevant to environmental monitoring. Environ Res 1982;29:247–255.
   PubMed Web of Science ®Google Scholar
• Robertson JG, Enzymes as a special class of therapeutic target: clinical drugs and modes of action. Curr Opin Struc Biol 2007;17:674–679.
   PubMed Web of Science ®Google Scholar
• Yılmaz H, Ciftci M, Beydemir S, Bakan E. Purification of glucose 6-phosphate dehydrogenase from chicken erythrocytes. investigation of some kinetic properties. Prep Bıochem Bıotech 2002;32:287–301.
   PubMed Web of Science ®Google Scholar
• Hisar O, Beydemir S, Gülçin I, Küfrevioğlu OI, Supuran CT. Effects of low molecular weight plasma inhibitors rainbow trout (Oncorhynchus mykiss) on human erythrocyte carbonic anhydrase-II isozyme activity in vitro and rat erythrocytes in vivo”. J Enz Inhib Med Ch 2005;20:35–39.
   PubMed Web of Science ®Google Scholar
• Pla A, Rodrigo L, Hernandez AF, Gil Lopez FO. Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem-Biol Interact 2007;167:63–70.
   PubMed Web of Science ®Google Scholar
• Furlong CE, Richter RJ, Chapline C, Crabb JW. Purification of Rabbit and Human Serum Paraoxonase. Biochemistry 1991;30:10133–10140.
   PubMed Web of Science ®Google Scholar